Contrast-enhanced ultrasound enables precision diagnosis of preoperative muscle invasion in bladder cancer: a prospective study

Abstract

Bladder cancer’s high mortality underscores the need for precise staging, especially to differentiate between nonmuscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) types. This prospective study evaluated the efficacy of contrast-enhanced ultrasound (CEUS) for preoperative staging, focusing on its ability to distinguish NMIBC from MIBC. Conducted from April 2020 to September 2021, the study involved 163 patients (median age: 64.0 years; 137 males, 26 females), with 133 NMIBC (81.6%) and 30 MIBC (18.4%). Each patient underwent CEUS followed by transurethral resection of bladder tumor or radical cystectomy. CEUS demonstrated high diagnostic accuracy in determining muscle invasion status (sensitivity 83.3%, specificity 92.5%, accuracy 90.8%, area under the receiver operating characteristic curve [AUC] 0.88). Comparative analyses against MRI (AUC 0.77) showed CEUS outperforming in muscle invasion detection. Combining CEUS with MRI improved diagnostic accuracy, particularly when MRI vesical imaging reporting and data system score was 3 points. The combined approach achieved an AUC of 0.73, with sensitivity, specificity, and accuracy of 76.2, 70.2, and 71.6%, respectively. Thus, CEUS emerges as a valuable diagnostic tool for preoperative staging of bladder cancer, particularly in its role in assessing muscle invasion status and thereby aiding in clinical decision-making and intervention outcomes.

Keywords

bladder cancer / contrast-enhanced ultrasound / muscle invasion / precision diagnosis / prospective study

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

[2] Flaig TW, Spiess PE, Agarwal N, et al. Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020; 18(3): 329-354.

[3] Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022; 81(1): 75-94.

[4] Lai AL, Law YM. VI-RADS in bladder cancer: overview, pearls and pitfalls. Eur J Radiol. 2023; 160: 110666.

[5] Saita A, Lughezzani G, Buffi NM, et al. Assessing the feasibility and accuracy of high-resolution microultrasound imaging for bladder cancer detection and staging. Eur Urol. 2020; 77(6): 727-732.

[6] Gupta VG, Kumar S, Singh SK, Lal A, Kakkar N. Contrast enhanced ultrasound in urothelial carcinoma of urinary bladder: an underutilized staging and grading modality. Cent European J Urol. 2016; 69(4): 360-365.

[7] Dietrich CF, Nolsøe CP, Barr RG, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver—update 2020 - WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Aktualisierte Leitlinien und Empfehlungen für die gute klinische Praxis für CEUS der Leber. Ultraschall Med. 2020; 41(5): 562-585.

[8] Jakobsen JA, Oyen R, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Safety of ultrasound contrast agents. Eur Radiol. 2005; 15(5): 941-945.

[9] Beckmann S, Simanowski JH. Update in contrast-enhanced ultrasound. Visc Med. 2020; 36(6): 476-486.

[10] Panebianco V, Narumi Y, Altun E, et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (vesical imaging-reporting and data system). Eur Urol. 2018; 74(3): 294-306.

[11] Ruiz de Porras V, Pardo JC, Etxaniz O, Font A. Neoadjuvant therapy for muscle-invasive bladder cancer: current clinical scenario, future perspectives, and unsolved questions. Crit Rev Oncol Hematol. 2022; 178: 103795.

[12] Cornelissen SWE, Veenboer PW, Wessels FJ, Meijer RP. Diagnostic accuracy of multiparametric MRI for local staging of bladder cancer: a systematic review and meta-analysis. Urology. 2020; 145: 22-29.

[13] Pecoraro M, Takeuchi M, Vargas HA, et al. Overview of VI-RADS in bladder cancer. AJR Am J Roentgenol. 2020; 214(6): 1259-1268.

[14] Dietrich CF, Nolsøe CP, Barr RG, et al. Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med Biol. 2020; 46(10): 2579-2604.

[15] Wang F, Zhang Q, Yan K, et al. 3D-CEUS/MRI-CEUS fusion imaging vs 2D-CEUS after locoregional therapies for hepatocellular carcinoma: a multicenter prospective study of therapeutic response evaluation. Eur Radiol. 2024.

[16] Zhou Y, Ding J, Qin Z, et al. Combination of CT/MRI LI-RADS with CEUS can improve the diagnostic performance for HCCs. Eur J Radiol. 2022; 149: 110199.

[17] Bicchetti M, Simone G, Giannarini G, et al. A novel pathway to detect muscle-invasive bladder cancer based on integrated clinical features and VI-RADS score on MRI: results of a prospective multicenter study. Radiol Med. 2022; 127(8): 881-890.

[18] Li C, Gu Z, Ni P, et al. The value of contrast-enhanced ultrasound and magnetic resonance imaging in the diagnosis of bladder cancer. J Cancer Res Ther. 2021; 17(5): 1179-1185.

[19] Ou Q, Lu Z, Cai G, et al. Unraveling the influence of metabolic signatures on immune dynamics for predicting immunotherapy response and survival in cancer. MedComm—Future Med. 2024; 3: e89.

[20] Zhao J, Jiang O, Chen X, et al. Development and validation of a prediction model for metastasis in colorectal cancer based on LncRNA CRNDE and radiomics. MedComm-Future Med. 2022; 1: e6.

[21] Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology. 2015; 277(3): 826-832.

[22] Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016; 70(1): 106-119.

[23] Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 2018; 73(4): 560-569.

[24] Zhao L, Leng Y, Hu Y, et al. Understanding decision curve analysis in clinical prediction model research. Postgrad Med J. 2024; 100(1185): 512-515.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.